Abstract: Plerixafor is a CXC chemokine receptor 4 (CXCR4) antagonist that mobilizes hematopoietic stem cells from the bone marrow to the peripheral blood. Plerixafor was approved by the National Medical Products Administration (NMPA) to mobilize autologous hematopoietic stem cells in patients with non-Hodgkin's lymphoma (LNHL) in December 2018 and in patients with multiple myeloma in August 2020. So far, although plerixafor has been marketed abroad for more than 10 years and has been widely used in clinical practice, there is no relevant consensus regarding its standard clinical application in China because of its short marketing time in China and little clinical practice experience. This article summarizes relevant research data on plerixafor and establishes Chinese expert consensus to provide a reference for clinicians.